Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic Capillary Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optimized Assay Conditions

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhang, Huidan ^a   Song, Jin ^a   Ren, Hui ^b   Xu, Zhangrun ^c   Wang, Xiaonan ^a   Shan, Lianfeng ^a   Fang, Jin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Department of Colon Surgery   (China)

^c NORTHEASTERN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENOMIC DNA;

ADULT; AGED; ARTICLE; CAPILLARY ELECTROPHORESIS; CODON; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA MARKER; FEMALE; FLUORESCENCE ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROFLUIDIC ANALYSIS; ONCOGENE K RAS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; WILD TYPE;

ADULT; AGE FACTORS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, CAPILLARY; ELECTROPHORESIS, MICROCHIP; FEMALE; HUMANS; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84872774640     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054510     Document Type: Article

References (60)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
3. Ma WW, Adjei AA, (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111-137.
4. Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, et al. (2012) Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies. Cancer 118: 1523-1532.
5. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, et al. (2011) Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial. Oncologist 16: 1557-1564.
6. Mayo SC, Pawlik TM, (2009) Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 3: 131-144.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
9. Waldner MJ, Neurath MF, (2010) The molecular therapy of colorectal cancer. Mol Aspects Med 31: 171-178.
10. Winder T, Lenz HJ, (2010) Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 36: 550-556.
11. Fariña Sarasqueta A, Moerland E, de Bruyne H, de Graaf H, Vrancken T, et al. (2011) SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn 13: 199-205.
12. Shackleton M, Quintana E, Fearon ER, Morrison SJ, (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.
13. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, et al. (2009) High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136: 459-470.
14. Marchetti A, Gasparini G, (2009) K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 833-834.
15. Zhang H, Wang X, Ma Q, Zhou Z, Fang J, (2011) Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis. Lab Invest 91: 788-798.
16. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-1096.
17. Schimanski CC, Zimmermann T, Schmidtmann I, Gockel I, Lang H, et al. (2010) K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. Int J Colorectal Dis 25: 181-186.
18. Scholtka B, Schneider M, Melcher R, Katzenberger T, Friedrich D, et al. (2009) A gene marker panel covering the Wnt and the Ras- Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans. Cancer Epidemiol 33: 123-129.
19. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, et al. (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res14: 7884-7895.
20. Milano G, Etienne-Grimaldi MC, Dahan L, Francoual M, Spano JP, et al. (2008) Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19: 2033-2038.
21. Loda M, (1994) Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Hum Pathol 25: 564-571.
22. Cavallini A, Valentini AM, Lippolis C, Campanella D, Guerra V, et al. (2010) KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res 30: 5251-5256.
23. Lanthaler AJ, Spizzo G, Mitterer M, Mian C, Mazzoleni G, (2011) Interlaboratory comparison of K-ras testing by real-time PCR and RFLP in colorectal cancer samples. Diagn Mol Pathol 20: 90-93.
24. Xiao SX, Wu L, Wang DB, Hu JG, Liu HP, et al. (1997) Detection of mutated K-ras at codon 12 with a modified PCR-RFLP technique. Prog Biochem Biophys 24: 375-378.
25. Schimanski CC, Linnemann U, Berger MR, (1999) Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59: 5169-5175.
26. Nishikawa T, Maemura K, Hirata I, Matsuse R, Morikawa H, et al. (2002) A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Clin Chim Acta 318: 107-112.
27. Kleparník K, Bocek P, (2007) DNA diagnostics by capillary electrophoresis. Chem Rev 107: 5279-5317.
28. Ohno K, Tachikawa K, Manz A, (2008) Microfluidics: applications for analytical purposes in chemistry and biochemistry. Electrophoresis 29: 4443-4453.
29. Akamine R, Yatsushiro S, Yamamura S, Kido J, Shinohara Y, et al. (2009) Direct endonuclease digestion and multi-analysis of restriction fragment length polymorphisms by microchip electrophoresis. J Pharm Biomed Anal 50: 947-953.
30. Minucci A, Delibato E, Castagnola M, Concolino P, Ameglio F, et al. (2008) Identification of RFLP G6PD mutations by using microcapillary electrophoretic chips (Experion). J Sep Sci 31: 2694-2700.
31. Qin J, Liu Z, Wu D, Zhu N, Zhou X, et al. (2005) Genotyping the-6A/G functional polymorphism in the core promoter region of angiotensinogen gene by microchip electrophoresis. Electrophoresis 26: 219-224.
32. Chowdhury J, Kagiala GV, Pushpakom S, Lauzon J, Makin A, et al. (2007) Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events, J Mol Diagn. 9: 521-529.
33. Nachamkin I, Panaro NJ, Li M, Ung H, Yuen PK, et al. (2001) Agilent 2100 bioanalyzer for restriction fragment length polymorphism analysis of the Campylobacter jejuni flagellin gene. J Clin Microbiol 39: 754-757.
34. Jia ZJ, Fang Q, Fang ZL, (2004) Bonding of glass microfluidic chips at room temperatures. Anal Chem 76: 5597-5602.
35. Fang Q, Xu GM, Fang ZL, (2002) A high-throughput continuous sample introduction interface for microfluidic chip-based capillary electrophoresis systems. Anal Chem 74: 1223-1231.
36. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, et al. (2012) PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 11: 143-150.
37. Mao C, Zhou J, Yang Z, Huang Y, Wu X, et al. (2012) KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 7: e36653.
38. Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, et al. (2011) Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 105: 246-254.
39. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, et al. (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901-4914.
40. Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E, et al. (2010) A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 12: 292-299.
41. Götz S, Karst U, (2007) Recent developments in optical detection methods for microchip separations. Anal Bioanal Chem 387: 183-192.
42. Jiang GF, Attiya S, Ocvirk G, Lee WE, Harrison DJ, (2000) Red diode laser induced fluorescence detection with a confocal microscope on a microchip for capillary electrophoresis. Biosens Bioelectron 14: 861-869.
43. Benson SC, Mathies RA, Glazer AN, (1993) Heterodimeric DNA-binding dyes designed for energy transfer: stability and applications of the DNA complexes. Nucleic Acids Res 21: 5720-5726.
44. Benson SC, Mathies RA, Glazer AN, (1993) Heterodimeric DNA-binding dyes designed for energy transfer: stability and applications of the DNA complexes. Nucleic Acids Res 21: 5727-5735.
45. Gebauer P, Bocek P, (2009) Electrophoretic sample stacking. Electrophoresis30: S27-S33.
46. Beard NP, Zhang CX, deMello AJ, (2003) In-column field-amplified sample stacking of biogenic amines on microfabricated electrophoresis devices. Electrophoresis 24: 732-739.
47. Malá Z, Krivánková L, Gebauer P, Bocek P, (2007) Contemporary sample stacking in CE: a sophisticated tool based on simple principles. Electrophoresis 28: 243-253.
48. Malá Z, Slampová A, Gebauer P, Bocek P, (2009) Contemporary sample stacking in CE. Electrophoresis 30: 215-229.J Chromatogr A. 1051: 147-153.
49. Xu F, Jabasini M, Zhu B, Ying L, Cui X, et al. (2004) Single-step quantitation of DNA in microchip electrophoresis with linear imaging UV detection and fluorescence detection through comigration with a digest. J Chromatogr A 1051: 147-153.
50. Yang Y, Boysen RI, Hearn MT, (2006) Optimization of field-amplified sample injection for analysis of peptides by capillary electrophoresis-mass spectrometry. Anal Chem 78: 4752-4758.
51. Petersen NJ, Nikolajsen RP, Mogensen KB, Kutter JP, (2004) Effect of Joule heating on efficiency and performance for microchip-based and capillary-based electrophoretic separation systems: a closer look. Electrophoresis 25: 253-269.
52. Evenhuis CJ, Haddad PR, (2009) Joule heating effects and the experimental determination of temperature during CE. Electrophoresis 30: 897-909.
53. Bornholdt J, Hansen J, Steiniche T, Dictor M, Antonsen A, et al. (2008) K-ras mutations in sinonasal cancers in relation to wood dust exposure. BMC Cancer 8: 53.
54. Ko JM, Cheung MH, Wong CM, Lau KW, Tang CM, et al. (1998) Ki-ras codon 12 point mutational activation in Hong Kong colorectal carcinoma patients.Cancer Lett. 134: 169-176.
55. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL, (2005) Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet 158: 55-60.
56. Capella G, Cronauer-Mitra S, Pienado MA, Perucho M, (1991) Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 93: 125-131.
57. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, et al. (1989) Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2: 353-356.
58. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S, (1991) Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 49: 875-879.
59. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, et al. (2008) Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14: 579-584.
60. Luo JD, Chan EC, Shih CL, Chen TL, Liang Y, et al. (2006) Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 34: e12.